Neuroone Medical Technologies (NMTC) Non-Current Deferred Tax Liability (2021 - 2022)
Neuroone Medical Technologies (NMTC) posted Non-Current Deferred Tax Liability of $140538.0 for Q3 2022, up 118.94% on a QoQ basis from $64189.0 in Q3 2021, and up 118.94% year-over-year from $64189.0 in Q3 2021.
Neuroone Medical Technologies (NMTC) Non-Current Deferred Tax Liability (2021 - 2022) Analysis & Trends
Neuroone Medical Technologies' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $140538.0 for Q3 2022.
- Quarterly Non-Current Deferred Tax Liability rose 118.94% year-over-year to $140538.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $140538.0 (up 118.94% YoY) and the FY2022 annual result came in at $140538.0, up 118.94% from the prior year.
- Non-Current Deferred Tax Liability was $140538.0 for Q3 2022 at Neuroone Medical Technologies, up from $64189.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $140538.0 in Q3 2022 and bottomed at $64189.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Neuroone Medical Technologies | 7.99 Mn | 5.19 Mn | 990,264.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 140,538.00 |
| Sep 30, 2022 | 140,538.00 |
| Sep 30, 2021 | 64,189.00 |
| Sep 30, 2021 | 64,189.00 |